Therapy Areas: Infectious Diseases
Co-Diagnostics, LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology
31 October 2018 - - US-based molecular diagnostics company Co-Diagnostics, Inc. (NASDAQ: CODX) and LGC, Biosearch Technologies, a specialist in the design, development, and manufacture of sophisticated, custom oligonucleotide-based tools and associated reagents for applied markets, have signed an exclusive license agreement related to the use of the company's CoPrimer technology for both research and commercial applications, the companies said.

This agreement is the result of a joint development project conducted over the past year to test the performance of CoPrimers in multiplexed reactions when locating specific genetic traits in seed products and genetic mutations, including SNP detection.

Biosearch Technologies, the complete genomics portfolio from LGC, operates from cGMP and ISO 13485:2016 certified production facilities, and has been the sole manufacturer of Co-Diagnostics' CoPrimers since 2013.

LGC is an international leader in the extended life sciences sector, including human healthcare, agri-food and the environment. LGC provides a comprehensive range of reference materials, proficiency testing schemes, genomics reagents and instrumentation, as well as research and measurement services.

Its scientific tools and solutions enable organisations to advance research, develop new products and form an essential part of their quality and compliance procedures.

Mark Dearden is available for interview. Biosearch Technologies' logo and pictures available on request.

LGC is an international leader in the extended life sciences sector, including human healthcare, agri-food and the environment. LGC provides a range of reference materials, proficiency testing schemes, genomics reagents and instrumentation, as well as research and measurement services.

Its scientific tools and solutions enable organisations to advance research, develop new products and form an essential part of their quality and compliance procedures.

LGC's 2,300 employees include internationally-recognized scientists who are experts in their field. Headquartered in London, it operates out of 19 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.

LGC has been home to the UK government Chemist for more than 100 years and is the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement. LGC has been privately-owned since 1996 and has diversified through internal investment and acquisition to be an international leader in its chosen niche markets.

LGC is now owned by funds affiliated with KKR.

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology.

The company's technology is utilised for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Login
Username:

Password: